What the Study Found (In Plain English)
Published in Obstetrics and gynecology (2018), this phase iii randomized trial evaluating human clinical outcomes investigated: To evaluate efficacy, endometrial safety, and overall safety of a single-capsule 17β-estradiol-progesterone (TX-001HR) for treating menopausal moderate-to-severe vasomotor symptoms. Key clinical takeaway: No endometrial hyperplasia was observed while single-capsule estradiol-progesterone provided clinically meaningfully improvements in moderate-to-severe vasomotor symptoms.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Obstetrics and gynecology, 2018-07-15; Phase III Randomized Trial; Rigor 88/100): No endometrial hyperplasia was observed while single-capsule estradiol-progesterone provided clinically meaningfully improvements in moderate-to-severe vasomotor symptoms.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.